Abstracts tagged "Wegener’s"

Abstract Number: 0714 • ACR Convergence 2024
Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba², Robert McBane¹ and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an acutely life-threating presentation of ANCA-associated vasculitis (AAV), and patients with AAV are at increased risk of venous thromboembolic…
Abstract Number: 2487 • ACR Convergence 2024
Comparing Circulating Protein Profiles in Patients with Active Myeloperoxidase (MPO) vs Proteinase-3 (PR3) Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
Colebrook Johnson¹, David O'Dea¹, Natalie Atallah¹, Gary Reynolds¹, Bohang Jiang¹, Shruthi Srivatsan¹, Zachary Williams¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA type (e.g., PR3-, MPO-ANCA) may be a better way to subgroup patients with ANCA-associated vasculitis (AAV) than phenotype (e.g., granulomatosis with polyangiitis [GPA]).…
Abstract Number: 0682 • ACR Convergence 2023
Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients
Gunter Assmann¹, Christoph Rittich¹, Frank Neumann², Udo Kellner³, Ryszard Turkiewicz⁴, Joerg Radermacher⁵, Peter Lamprecht⁶ and Björn Tampe⁷, ¹RUB University Hospital Minden - Rheumatology, Minden, Germany, ²Jose Carreras Center Saarland, Homburg, Germany, ³RUB University Hospital Minden - Pathology, Minden, Germany, ⁴RUB University Hospital Minden - Pulmonology, Minden, Germany, ⁵RUB University Hospital Minden - Nephrology, Minden, Germany, ⁶University Hospital Luebeck - Schleswig-Holstein, Luebeck, Germany, ⁷University Clinic department Goettingen - Nephrology, Goettingen, Germany
Background/Purpose: The orally administered C5a receptor inhibitor avacopan is approved for the therapy of ANCA-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide and shows…
Abstract Number: 0681 • ACR Convergence 2023
Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis
Itay Marmor¹, Katelin Nickel², Matthew Keller², Guy Hazan³, Kevin Baszis⁴, Anthony French⁵ and Mary Hartman², ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Washington University in St. Louis, St. Louis, MO, ³Soroka University Medical Center, Beer Sheva, Israel, ⁴Washington Univ in St. Louis School of Medicine, St. Louis, MO, ⁵Washington University School of Medicine, St. Louis, MO
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), often manifests with life-threatening complications. Cyclophosphamide (CYC) and rituximab…
Abstract Number: 0513 • ACR Convergence 2022
The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Jessica Bloom¹, Kaci Pickett², Lori Silveira², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland¹, Christian Pagnoux⁹, Rennie Rhee¹⁰, Philip Seo¹¹, Ulrich Specks¹², Kenneth J. Warrington¹², Robert Fuhlbrigge¹ and Peter Merkel¹⁰, ¹University of Colorado, Denver, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, ⁸VA Boston Healthcare System, Boston, MA, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN
Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated…
Abstract Number: 1418 • ACR Convergence 2020
Clinical Presentations and Follow-up Results of Granulomatosis with Polyangiitis: An Analysis of 8 Years Clinical Experience with 220 Patients from a National Referral Center
Seyed Behnam Jazayeri¹, Farzaneh Kianifar², Samira Alesaeidi², Soheil Tavakolpour³, Amir Teimourpour⁴ and Sasan Dabiri², ¹Tehran university of medical scienses, Tehran, Iran, ²Tehran university of medical sciences, Tehran, Iran, ³Dana-faber cancer institute, Harvard Medical School, Boston, MA, ⁴Department of epidemiology and bio-statistics, Tehran university of medical sciences, Tehran, Iran
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a rare and life-threatening autoimmune disease. Due to the extremely low prevalence of GPA, monitoring of clinical characteristics and…
Abstract Number: 1438 • ACR Convergence 2020
Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)
Jason Springer¹ and Ryan Funk², ¹University of Kansas Medical Center, Overland Park, KS, ²UNIVERSITY OF KANSAS, Kansas City, KS
Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].